KOSDAQCosmetics086710

Sunjin Beauty Science

₩5,790▼ 1.86%2026-11-18 close
Market Cap
₩70.7B
Turnover
₩13,815,225
Volume
2.4K
Shares out.
12.2M
PER
28.6×
PBR
0.9×
EPS
₩203
Dividend Yield
3.45%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales expanding, profit recovery under way

Sales rose to KRW 80.8 billion in 2025 while operating profit fell to KRW 6.06 billion. Operating profit then grew for two consecutive quarters into 2026 Q3, but a net loss attributable to controlling shareholders in 2026 Q3 leaves the durability of the recovery unconfirmed.

  1. 1

    Sales climbed from KRW 64.3 billion in 2022 to KRW 80.8 billion in 2025, though growth slowed to 1.8% in 2025.

  2. 2

    Operating profit fell 43.0% to KRW 6.06 billion in 2025, and the 7.5% operating margin was the lowest in 2022–2025.

  3. 3

    Operating profit rose from KRW 1.52 billion in 2026 Q1 to KRW 1.68 billion in Q2 and KRW 2.24 billion in Q3, two consecutive quarterly increases.

  4. 4

    2026 Q3 posted a net loss attributable to controlling shareholders of KRW 1.76 billion, and the last four quarters total KRW 2.43 billion in net income attributable to controlling shareholders.

  5. 5

    The company set a 2026 sales target of KRW 100 billion and said it had raised its payout ratio from about 7% to 41%.

02

Business structure

Sunjin Beauty Science is a cosmetic ingredient maker whose core products are UV filters, microbeads and skincare materials. Based on press reports, standalone cosmetic material sales in 2025 were KRW 50.8 billion, the largest share of its product lines.

Of the KRW 29.6 billion in cosmetic material sales in the first half of 2026, microbeads contributed KRW 16.9 billion, followed by UV filters at KRW 9.9 billion and skincare materials at KRW 2.8 billion. Exports in the same half were about KRW 21.8 billion, so overseas exposure remains high.

The company says it exports to more than 50 countries and that overseas sales account for about 80% of the total. Its business has widened from ingredient supply into clinical testing, ODM and OEM production, and its own brand.

ODM and OEM sales rose 127.4% to KRW 548 million in 2025 and reached KRW 740 million in the first half of 2026, already above the full-year 2025 figure.

The irecipe brand grew from KRW 143.9 million in 2025 to KRW 117 million in the first half of 2026, and clinical sales rose from KRW 166 million to KRW 174.7 million over the same period. Ingredient sales still make up the large majority of revenue. In July 2025 the company completed a KRW 25.4 billion OTC finished-goods plant in Jangham, Seocheon, Chungnam.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩18.9B₩700M3.7%
2025Q4₩17.8B-₩400M−2.3%
2026Q1₩22.7B₩1.5B6.7%
2026Q2₩23.6B₩1.7B7.1%
2026Q3₩22.6B₩2.2B9.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩64.3B₩5.3B₩19.6B8.3%30.4%102.7%
2023₩72.6B₩9B₩5.6B12.5%8.0%72.7%
2024₩79.4B₩10.6B₩9.1B13.4%11.6%86.0%
2025₩80.8B₩6.1B₩6B7.5%7.0%95.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Sales in the disclosed annual figures rose from KRW 64.3 billion in 2022 to KRW 72.6 billion in 2023 (up 12.9%), KRW 79.4 billion in 2024 (up 9.3%) and KRW 80.8 billion in 2025 (up 1.8%). Sales have increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022–2025.

Operating profit rose from KRW 5.32 billion in 2022 to KRW 9.04 billion in 2023 (up 70.0%) and KRW 10.6 billion in 2024 (up 17.6%), then fell to KRW 6.06 billion in 2025 (down 43.0%).

The company attributed the 2025 decline to higher fixed and selling and administrative costs from the new ODM plant and expanded new businesses, along with marketing spending for its own brand.

The company has described 2025 as its fifth consecutive year of record sales, and said the profit decline reflects new-business investment rather than structural deterioration. The operating margin moved from 8.3% in 2022 to 12.5% in 2023 and 13.4% in 2024, before falling to 7.5% in 2025.

Net income including non-controlling interests fell from KRW 10.4 billion in 2024 to KRW 7.32 billion in 2025. Net income attributable to controlling shareholders went from KRW 19.6 billion in 2022 to KRW 5.61 billion in 2023, KRW 9.12 billion in 2024 and KRW 5.96 billion in 2025.

Operating cash flow was KRW 2.2 billion in 2023 and recovered to KRW 10.5 billion in 2025. The debt ratio rose from 72.7% in 2023 to 95.3% in 2025, when total equity was KRW 89 billion, of which KRW 84.6 billion belonged to controlling shareholders.

By quarter, the company swung to an operating loss of KRW 405 million in 2025 Q4 and returned to operating profit of KRW 1.52 billion in 2026 Q1. Operating profit then reached KRW 1.68 billion in Q2 and KRW 2.24 billion in Q3, two consecutive increases, with Q3 up 221.5% year on year.

However, 2026 Q3 posted a net loss attributable to controlling shareholders of KRW 1.76 billion, a swing into loss from the prior-year quarter, while Q3 sales of KRW 22.6 billion rose 19.9% year on year.

05

Industry analysis

The company describes cosmetic ingredient production as a capital-intensive, B2B business in which supplier trust creates high entry barriers, which helps explain why domestic ingredient makers have developed more slowly than finished-goods, OEM or packaging peers.

Sunjin Beauty Science says it became the first domestic cosmetic ingredient maker to pass an FDA on-site inspection in 2019, and it claims to have been the second company worldwide to mass-produce monodisperse microbeads, in 2009.

Demand from global brands is shaped by inventory cycles, and China-related sales have been volatile since the COVID-19 period, according to brokerage commentary. Inventory adjustments at overseas distributors were cited as a factor limiting 2025 sales growth.

Large domestic ODM peers such as Cosmax and Kolmar Korea have much greater finished-goods capacity, while Sunjin Beauty Science starts from ingredients and extends into finished products, so its competitive position differs.

Its strength lies in linking ingredient development, clinical testing, finished goods and brands. Whether that chain converts existing ingredient customers into ODM customers is the central variable in its competitive position.

Slowing growth and falling profitability in the ingredient business are also flagged as challenges in assessing its position against the sector.

06

Outlook

The company has set a 2026 target of more than KRW 100 billion in sales and expects ODM expansion and direct global sales to drive growth and margin improvement. That target assumes a large rise from KRW 80.8 billion in 2025.

Two dedicated hydrogel mask and patch production lines were built with about KRW 3.2 billion of investment, and the company says mass production can begin within three to four weeks once formulation and packaging are fixed.

Its minimum order quantity is about 20,000 sheets, below the typical 80,000-sheet minimum for hydrogel masks. The US subsidiary began direct sales in February 2025 and has set 2026 targets of US$3.5 million in sales and an operating profit.

The Italian subsidiary reported 8% sales growth and 22% operating profit growth in 2025, and will start direct sales in Spain in 2026. The payout ratio was raised from about 7% to 41%, with the company saying it intends to maintain a high payout.

However, quarterly sales in 2026 Q1 through Q3 all stayed in the mid-KRW 20 billion range, so reaching the full-year target would require Q4 2026 sales to rise sharply from recent quarters. Slowing growth and weaker profitability in the ingredient business remain challenges.

Utilization and order wins at the KRW 25.4 billion OTC plant are cited as the variables that will determine the next growth stage.

07

Valuation

PER
28.6×
PBR
0.9×
ROE
2.9%
EPS
₩203
BPS
₩6,784
Dividend per share
₩200

The current multiples are hard to read on earnings alone, because net income attributable to controlling shareholders over the last four quarters totals KRW 2.43 billion. The 2026 Q3 net loss means earnings-based multiples should be read alongside the quarterly trend.

The price-to-book ratio sits below 1x, meaning the share price is trading under the book value attributable to controlling shareholders. Controlling shareholders' equity of KRW 84.6 billion at end-2025 makes up most of total equity of KRW 89 billion, and the debt ratio rose from 72.7% in 2023 to 95.3% in 2025.

The company has announced a payout ratio increase from about 7% to 41%, and the actual dividend amount will be set at the annual shareholder meeting. Dividend comparisons should be updated when the confirmed dividend amount is disclosed. Valuation interpretation depends on the pace of profit recovery and on changes in the capital structure.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Sales target and production structure

The company has set a 2026 sales target of KRW 100 billion, and sales rose for three consecutive years from 2023 through 2025 to KRW 80.8 billion. According to the company, the OTC plant completed in July 2025 and its ODM lines link ingredients to finished products. ODM and OEM sales reached KRW 740 million in the first half of 2026, already above the full-year 2025 figure.

Quarterly profit recovery

Operating profit turned positive at KRW 1.52 billion in 2026 Q1, then rose to KRW 1.68 billion in Q2 and KRW 2.24 billion in Q3, two consecutive increases. Q3 operating profit was up 221.5% year on year. Whether the operating margin continues this trend is the next point to check in the upcoming regular report.

Shareholder returns and overseas units

The company has announced a payout ratio increase from about 7% to 41%. It says overseas sales make up about 80% of the total and that it exports to more than 50 countries. The company also said its Italian subsidiary recorded 8% sales growth and 22% operating profit growth in 2025.

09

Bear factors

Profit decline in 2025

Operating profit fell 43.0% to KRW 6.06 billion in 2025, and the 7.5% operating margin was the lowest in 2022–2025. Net income attributable to controlling shareholders fell 34.6% to KRW 5.96 billion. The company attributes the decline to higher fixed and selling costs tied to the new ODM plant and new businesses.

Swing to loss in 2026 Q3

Net loss attributable to controlling shareholders was KRW 1.76 billion in 2026 Q3, a swing into loss from the prior-year quarter. Operating profit was positive in the same quarter, which points to items below operating profit. The cause needs to be checked in the next regular reports. Over the last four quarters, net income attributable to controlling shareholders totals only KRW 2.43 billion.

Slowing ingredient business

According to a Bloter report, consolidated operating profit in the first half of 2026 was KRW 3.2 billion, down 44.8% from KRW 5.8 billion a year earlier. Slowing growth and weaker profitability in the ingredient business were flagged as challenges.

Because new-business revenue is still small, the pace of recovery in ingredients largely determines overall results.

10

Risk factors

Transition costs

With the KRW 25.4 billion OTC plant and ODM lines now operating, fixed costs and depreciation have risen. Marketing for the irecipe brand also weighs on operating profit. If new-business revenue does not grow enough to offset these costs, the profit recovery could remain limited.

Overseas demand and inventory cycles

With overseas sales at about 80% of the total, results are sensitive to trade conditions. Inventory adjustments at overseas distributors were cited as a factor that limited 2025 sales growth. Volatility in China-related sales also remains a source of variability for the ingredient business.

Rising leverage

The debt ratio rose from 72.7% in 2023 to 95.3% in 2025. Of total equity of KRW 89 billion at end-2025, KRW 84.6 billion belonged to controlling shareholders. Combined with the higher payout plan and continuing facility investment, this could reduce financial flexibility.

11

What to watch next

  1. Late March 2027

    Annual report for fiscal 2026. Compare full-year sales with the company's KRW 100 billion target, and check 2026 Q4 operating results, items below operating profit, and whether the operating margin recovered.

  2. Around March 2027 (annual shareholder meeting)

    Check the dividend resolution at the annual shareholder meeting, which was held on March 26 in the prior year. Whether the 41% payout policy translates into the actual dividend amount will show how the return policy is being executed.

  3. Mid-May 2027

    Q1 2027 quarterly report. Check whether net income attributable to controlling shareholders returns to profit after the 2026 Q3 loss, along with ingredient profitability and new ODM customer wins.

12

Overall view

Sunjin Beauty Science posted sales of KRW 80.8 billion in 2025, rising for three consecutive years from 2023, but operating profit fell 43.0% to KRW 6.06 billion, so sales and profit moved in different directions.

In 2026, operating profit turned positive in Q1 and then rose in Q2 and Q3, with Q3 up 221.5% year on year. However, a net loss attributable to controlling shareholders of KRW 1.76 billion in 2026 Q3 shows that the recovery has not yet carried through below the operating line.

The company has set a KRW 100 billion sales target for 2026 and a 41% payout ratio, but quarterly sales from Q1 through Q3 stayed in the mid-KRW 20 billion range, so reaching the target would require a sharp rise in Q4 sales.

Strengths include the completed manufacturing infrastructure, ODM growth and overseas expansion. Weaknesses include fixed-cost burden, slowing ingredient sales and a higher debt ratio.

The next checkpoints are whether the 2026 annual report shows the sales target was reached and what caused the below-operating-line loss.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. sunjinbs.co.kr
  2. sunjinbs.co.kr
  3. jobplanet.co.kr
  4. sunjinbs.co.kr
  5. saramin.co.kr
  6. catch.co.kr
  7. bizno.net
  8. meconomynews.com
  9. facebook.com
  10. m.news.nate.com
  11. news.nate.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. bloter.net
  15. dailyinvest.kr
  16. sunjinbs.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis